Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator is the standard therapy for acute ischaemic stroke in the first 4.5 hours after onset of neurological symptoms. The efficacy of IVT increases strongly the sooner it is initiated after onset of neurological symptoms. Intra-arterial thrombolysis (IAT) and mechanical thrombectomy are potentially valuable treatment options in patients with severe ischemic stroke caused by an occlusion in a proximal cerebral artery. Further research is needed to evaluate the safety and efficacy of IAT and mechanical thrombectomy a) compared with IVT within 4.5 hours of symptom onset, b) outside the time window for IVT, c) when there are contraindications for IVT, d) when IVT fails to ac...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 3 h of symptom ...
Timely reperfusion of brain ischaemic tissue is the main therapeutic target for acute stroke. In the...
Item does not contain fulltextIntravenous thrombolysis (IVT) with recombinant tissue plasminogen act...
Intravenous thrombolysis (IVT) is the evidence-based treatment of acute ischemic stroke in the first...
AbstractIntravenous thrombolysis (IVT) with alteplase remains the standard treatment for acute ische...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 3 h of symptom ...
Timely reperfusion of brain ischaemic tissue is the main therapeutic target for acute stroke. In the...
Item does not contain fulltextIntravenous thrombolysis (IVT) with recombinant tissue plasminogen act...
Intravenous thrombolysis (IVT) is the evidence-based treatment of acute ischemic stroke in the first...
AbstractIntravenous thrombolysis (IVT) with alteplase remains the standard treatment for acute ische...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
Objective To assess the feasibility, safety and preliminary efficacy of intra-arterial thrombolysis ...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Ran...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 3 h of symptom ...
Timely reperfusion of brain ischaemic tissue is the main therapeutic target for acute stroke. In the...